Sun Pharma Advanced Research Company Limited
Sun Pharma Advanced Research Company Ltd is engaged in the business of research and development (R&D) of pharmaceutical products.
What Sun files
- Others51
- Important12
- Updates11
- Board Meeting10
- PPTs4
- Results2
SPARC has applied to stock exchanges for reclassification of a group from 'Promoter' to 'Public' category. This move, if approved, could alter the company's ownership structure and increase public float perception.
SPARC's licensing partner Ocuvex received an FDA Complete Response Letter for PDP-716 NDA, delaying approval. The issue stems from manufacturing facility inspection findings, not the drug's efficacy or safety.
SPARC sold its Rare Paediatric Disease Priority Review Voucher (PRV) for US $195 million. This strategic sale aims to accelerate pipeline development and strengthen its external innovation strategy, utilizing funds from its Sezaby® approval.
SPARC clarified its valuation report following an NSE query, explaining why income-based valuation (DCF) is unsuitable. This is due to its R&D business, consistent losses, and lack of predictable revenue streams, making future projections difficult.
SPARC secured a Rare Pediatric Disease Priority Review Voucher (PRV) from the FDA for Sezaby® approval. This tradable PRV offers strategic flexibility, accelerating SPARC's pipeline development to bring new therapies to patients faster, addressing unmet medical needs.